The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

BioDrugs

Volumn 15, Issue 2, 2001, Pages 87-97

  Bresnihan, Barry ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PROSTAGLANDIN;

ANTIINFLAMMATORY ACTIVITY; CARTILAGE DEGENERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; GENE THERAPY; HUMAN; INJECTION SITE; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0035046629     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115020-00003     Document Type: Review

References (55)

1. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis. Advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43: 2619-33
2. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-60
3. Elliott MJ, Maini RM, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
4. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-7
5. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptonFc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9
7. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147
8. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986; 323: 86-9
9. Nawroth PP, Bank I, Handley D, et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J Exp Med 1986;163:1363-75
10. Vannier E, Dinarello CA. Histamine enhances interleukin (IL)-1 -induced IL-1 gene expression and protein synthesis via H-2 receptors in peripheral blood mononuclear cells: comparison with IL-1 receptor antagonist. J Clin Invest 1993; 92: 281-7
11. Ghivizzani SC, Kang R, Georgescu HI, et al. Constitutive intraarticular expression of human IL-1 following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997; 159: 3604-12
12. Colatta F, Dower SK, Sims JE, et al. The type II 'decoy' receptor: a novel regulatory pathway for interleukin-1. Immunol Today 1994; 15: 562-6
13. Dayer J-M, de Rochemonteix B, Burrus B, et al. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 1986; 77: 645-8
14. Seckinger P, Lowenthal JW, Williamson K, et al. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987; 139: 1546-9
15. Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27-55
16. Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis Clin North Amer 1998; 24: 615-28
17. Burger D, Chicheportiche R, Giri JG, et al. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995; 96: 38-41
18. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191:313-20
19. van den Berg WB. Lessons for joint destruction from animal models. Curr Opin Rheumatol 1997; 9: 221-8
20. Balavoine JF, DeRochemonteix B, Williamson K, et al. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 1986; 78: 1120-4
21. Smith RJ, Chin JE, Sam LM, et al. Biologic effects of interleukin-1 receptor antagonist protein on interleukin-1 stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991; 34: 78-83
22. Henderson B, Thompson RC, Hardingham T, et al. Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 1991; 3: 246-9
23. Schwab JH, Anderle SK, Brown RR, et al. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 1991 ; 59:4436-42
24. Woolley PH, Whalen JD, Chapman DC, et al. The effect of interleukin-1 receptor antagonist protein on type II collageninduced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36: 1305-14
25. Leuthwaite J, Blake SM, Hardingham TE, et al. The effect of recombinant human interleukin-1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J Rheurn 1994; 21: 467-72
26. van de Loo FAJ, Joosten LAB, van Lent PLEM, et al. Role of interleukin-1, tumor necrosis factor a, and interleukin-6 in cartilage, proteoglycan metabolism and destruction: effect of in situ blocking of murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164-72
27. van Lent PLEM, van de Loo FAJ, Holthuysen AEM, et al. Major role for interleukin-1 but not tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995; 22: 2250-8
28. Joosten LAB, Helsen MMA, van de Loo FAJ, et al. Anticytokine treatment of established type 11 collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFot, antiIL-l and IL-lra. Arthritis Rheum 1996; 39: 797-809
29. Bendele A, Sennello G, McAbee T, et al. Effects of interleukin1 receptor antagonist alone or in combination with methotrexate in adjuvant arthritic rats. J Rheumatol 1999; 26: 1225-9
30. Evans CH, Ghivazzani SC, Rang R, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1-16
31. Otani K, Nita I, Macaulay W, et al. Suppression of antigen-induced arthritis by gene therapy. J Immunol 1996; 156: 3558-62
32. Makarov SS, Olsen JC, Johnston WN, et al. Suppression of experimental arthritis by gene transfer of interleukin-1 receptor antagonist cDNA. Proc Natl Acad Sei U S A 1996; 93:402-6
33. Bakker AC, Joosten LAB, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893-900
34. Boggs SS, Patrene KD, Mueller GM, et al. Prolonged systemic expression of human IL-1 receptor antagonist (hlL-lra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hlL-lra cDNA. Gene Ther 1995; 2: 632-8
35. Hesse DG, Tracey KJ, Fong Y, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147-53
36. Waage A, Espevik T. Interleukin-1 potentiates the lethal effects of tumor necrosis factor/cachectin in mice. J Exp Med 1988; 167: 1987-92
37. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin- 1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79-84
38. Fisher CJ, Dhainaut J-FA, Opal SM, et al., for the Phase 3 rhlL-lra Sepsis Syndrome Study Group. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-43
39. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type 1 in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996; 39: 257-65
40. Schorlemmer HU, Kanzy EJ, Langner KD, et al. Immunomodulatory activity of recombinant IL-1 receptor (IL-1 -R) on models of experimental rheumatoid arthritis. Agents Actions 1993;39:c113-c6
41. Campion GV, Lesback ME, Lookabaugh J, et al. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1092-101
42. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204
43. Bresnihan B. Treatment of rheumatoid arthritis with interleukin-1 receptor antagonist. Ann Rheum Dis 1999; 58 (Suppl. I): 96-8
44. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40
45. Larsen A, Dale K, Eek M. Radiographie evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977; 18: 481-91
46. Jiang Y, Genant HK, Watt 1, et al. A multicenter, double-blind, dose-ranging, randomized and placebo controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologie progression and correlation of Genant and Larsen scoring methods. Arthritis Rheum 2000; 43: 1001-9
47. Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001; 40(1): 62-9
48. Dinarello CA. The role of interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732-4
49. Nuki G, Rozman B, Pavelka K, et al. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum 1997; 40: S224
50. Cohen S, Hurd E, Cush JJ, et al. Treatment of interleukin-1 receptor antagonist in combination with methotrexate in rheumatoid arthritis patients. Arthritis Rheum 1999; 42: S273
51. Evans CH, Robbins PD, Ghivizzani SC, et al. Results from the first human clinical trial of gene therapy for arthritis. Arthritis Rheum 1999; 42: S170
52. Bendele A, McAbee T, Sennello G, et al. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42:498-506
53. O'Dell JR. Anticytokine therapy: a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999; 340: 310-2
54. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93
55. Lipsky PE, van der Heijde DMFM, St Clair EN, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-1602